As of close of business last night, 10x Genomics Inc’s stock clocked out at $30.80, down -6.27% from its previous closing price of $32.86. On the day, 2277119 shares were traded.
Ratios:
To gain a deeper understanding of TXG’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 4.11 and its Current Ratio is at 4.69. In the meantime, Its Debt-to-Equity ratio is 0.13 whereas as Long-Term Debt/Eq ratio is at 0.11.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Guggenheim on December 14, 2023, initiated with a Buy rating and assigned the stock a target price of $60.
On December 13, 2023, Wolfe Research started tracking the stock assigning a Outperform rating and target price of $55.
BofA Securities Upgraded its Underperform to Neutral on December 12, 2023, whereas the target price for the stock was revised from $36 to $54.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Mar 04 ’24 when Saxonov Serge sold 4,660 shares for $44.00 per share. The transaction valued at 205,021 led to the insider holds 842,900 shares of the business.
Saxonov Serge sold 2,821 shares of TXG for $130,737 on Feb 22 ’24. The Chief Executive Officer now owns 847,560 shares after completing the transaction at $46.34 per share. On Feb 22 ’24, another insider, Hindson Benjamin J., who serves as the insider of the company, sold 2,613 shares for $46.34 each. As a result, the insider received 121,098 and left with 283,059 shares of the company.
Valuation Measures:
For the stock, the TTM Price-to-Sale (P/S) ratio is 5.93 while its Price-to-Book (P/B) ratio in mrq is 4.95.
Stock Price History:
Over the past 52 weeks, TXG has reached a high of $63.57, while it has fallen to a 52-week low of $32.68.
Shares Statistics:
A total of 105.04M shares are outstanding, with a floating share count of 98.01M. Insiders hold about 17.75% of the company’s shares, while institutions hold 76.01% stake in the company.
Earnings Estimates
As of right now, 15 analysts gave their recommendation on the stock of the company. On average, analysts expect EPS of -$0.5 for the current quarter, with a high estimate of -$0.31 and a low estimate of -$0.65, while EPS last year was -$0.44. The consensus estimate for the next quarter is -$0.48, with high estimates of -$0.36 and low estimates of -$0.59.
Analysts are recommending an EPS of between -$1.11 and -$2.29 for the fiscal current year, implying an average EPS of -$1.6. EPS for the following year is -$0.96, with 14 analysts recommending between -$0.33 and -$1.65.
Revenue Estimates
In the current quarter, 13 analysts expect revenue to total $142.8M. It ranges from a high estimate of $145.95M to a low estimate of $139.35M. As of the current estimate, 10x Genomics Inc’s year-ago sales were $128.82M, an estimated increase of 10.90% from the year-ago figure. For the next quarter, 13 analysts are estimating revenue of $157.25M, an increase of 7.10% less than the figure of $10.90% in the same quarter last year. There is a high estimate of $163.8M for the next quarter, whereas the lowest estimate is $149.83M.
A total of 15 analysts have provided revenue estimates for TXG’s current fiscal year. The highest revenue estimate was $685.5M, while the lowest revenue estimate was $672.3M, resulting in an average revenue estimate of $678.62M. In the same quarter a year ago, actual revenue was $618.73M, up 9.70% from the average estimate. Based on 15 analysts’ estimates, the company’s revenue will be $793.36M in the next fiscal year. The high estimate is $863M and the low estimate is $753.8M. The average revenue growth estimate for next year is up 16.90% from the average revenue estimate for this year.
